Innova Captab Limited · NSE:INNOVACAP
Innova Captab — Q3 FY25 Earnings Presentation
33 slides from Innova Captab's earnings presentation, Feb 5, 2025
Slide 1: Intimation of Investor Presentation (cover letter to exchanges)
INNOVA CAPTAB LIMITED 1281/1, Hilltop Industrial Estate, Near EPIP, Phase-I, Jharmajri, Baddi, Dist. Solan (H.P.)-173205 India. Phone: +91-1795-650820 February 05, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mum
Slide 2: Investor Presentation – 5th February 2025
INVESTOR PRESENTATION – 5th February 2025 1
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Dg ac all = Br a5 > a &) Company Overview “(e) CAPTAB
Slide 5: One of the leading Integrated Pharmaceutical Player
One of the leading Integrated Pharmaceutical Player FY24 Highlights ₹ 1,094 crores ₹ 167 crores ₹ 94 crores 9 Third Largest New Greenfield Total Income EBITDA Profit after Tax Manufacturing Blocks Finished Tablet and Capsule Multipurpose Plant (4 manufacturing 3 Baddi |1 Dehradun |1 Taloja | Manufac
Slide 6: Our Journey
Our Journey 2006 2010 2013 2015-17 2018-21 2022 2023-24 2025 Foundation Establishment of International Establishment of Further Expansion Strategic Expansion Acquisition of Sharon Commercialization of Cephalosporin GMP Marketing Arm Jammu Plant • Innova Captab plant Certification • Further • Commenc
Slide 7: Q3 & 9MFY25 Performance Highlights
Q3 & 9MFY25 Performance Highlights 6
Slide 8: MD's Commentary
MD’s Commentary We are delighted to report a healthy performance in Q3 and 9M FY25, driven by robust resilience in our core business operations and strategic advancements. Our revenue from operations registered YoY growth of 4.6% in Q3 FY25 and of 13.5% in 9M FY25. PAT demonstrated strong surge of 3
Slide 9: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue (₹ Crores) EBITDA (₹ Crores) PAT (₹ Crores) +5% 15.5% 16.3% 16.1% 8.3% 11.0% 10.8% Margin 318.2 316.5 302.5 +9% 51.9 +36% 50.9 46.9 35.0 34.2 25.1 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Q3FY24 Q2FY25 Q3FY25 Geography-Wise* (%) Business Areas (₹ Crores) 318
Slide 10: 9M FY25 Performance Highlights
9M FY25 Performance Highlights Revenue (₹ Crores) EBITDA (₹ Crores) PAT (₹ Crores) +13.5% 15.0% 15.8% 8.0% 10.6% Margin 928.9 +19% 818.7 147.1 +50.5% 123.2 98.7 65.6 9MFY24 9MFY25 9MFY24 9MFY25 9MFY24 9MFY25 Geography-Wise* (%) Business Areas (₹ Crores) 928.9 21% 818.7 141.9 Export 25% Sharon* 95.7
Slide 11: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crores) Q3 FY25 Q3 FY24 YoY Growth Q2 FY25 QoQ Growth 9M FY25 9M FY24 YoY Growth Revenue from Operations 316.5 302.5 4.6% 318.2 -0.5% 928.9 818.7 13.5% Other Income 4.3 2.3 2.2 8.7 6.8 Total Income 320.8 304.8 5.2% 320.4 0.1% 937.6 825.5 13.6%
Slide 12: Jammu Plant Commercialised
Jammu Plant Commercialised 4 New Blocks Dosages Offered Fiscal Benefits o Cephalosporin o Oral Solid Dosages Poised to benefit from: Total Capital • Central Government's 'New o Penicillin* o Dry Powder Injectables Central Sector Scheme’, for Investment of Capital Interest Subvention of 6% > ₹ 450 cr
Slide 13: Enhancing Manufacturing Capabilities continuously
Enhancing Manufacturing Capabilities continuously Jammu Plant3 Tablets 10,679 mn Sharon2 Capsules 1,440 mn Dry Powder Tablets and 547 mn 2,012 mn Injections Baddi Plant1 Capsules Dry Syrups 311 mn Tablets 8,192 mn 313 metric BFS* (Large Volume API Capsules 2,472 mn tonne Parenterals and 562 mn Respu
Slide 14: Key Strengths
Dg a al > GP BHSS) Key Strengths “(e) CAPTAB
Slide 15: Key Strengths
Key Strengths 01 02 03 Strong Capabilities to Diversified Product Customer Centric Deliver across the Portfolio Approach Globe 04 05 06 R&D Centric Experienced Consistent Financial Organization Promoters and Board Performance of Directors 14
Slide 16: 1. Diversified Product Portfolio
1. Diversified Product Portfolio 9MFY25 Revenue mix CDMO Offer multiple dosage forms Including- 1. 2,900+ CDMO Products | 190+ Oral solids | Oral Liquids | Dry syrups | Dry powder injectables | Ointments | 55% Customers Large Volume Parenterals | Respules • Our branded generics business focuses on d
Slide 17: 2. Customer Centric Approach
2. Customer Centric Approach Revenue from Customers with Number of CDMO Customers Revenue from CDMO (₹ crores) >5 years relationship1 (₹ crores) FY21 119 371 338 FY22 174 687 603 FY23 182 680 572 FY24 193 622 522 Cultivated Strong Relationships within the Indian Pharmaceutical Industry 190+ 14 of th
Slide 18: 3. State of the Art Manufacturing Capabilities
3. State of the Art Manufacturing Capabilities Annual Installed Capacity and Utilization Kathua, Jammu [4 Blocks] Utilized (%) Location Block Products Capacity in FY24 Upcoming R&D Baddi, Himachal Pradesh (2 Units) [3 Blocks] Facility in Panchkula, R&D Facility in Baddi, Himachal Pradesh Tablets 8,1
Slide 19: 4. R&D Centric Organisation
4. R&D Centric Organisation Robust Research and Development Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by the DSIR for its in-house R&D 01 work. State-of-the-art facility equipped with a comprehensive suite of necessary tools for developing solid oral a
Slide 20: 5. Experienced Promoters and Board of Directors
5. Experienced Promoters and Board of Directors Manoj Kumar Lohariwala Vinay Lohariwala Jayant Vasudeo Rao Archit Aggarwal Chairman & Whole-time Director Managing Director Whole-time Director Non-Executive Director ▪ Bachelor’s in Commerce from Mohta ▪ Bachelor’s in Engineering (Mechanical) ▪ Bachel
Slide 21: 6. Consistent Financial Performance
6. Consistent Financial Performance Revenue from Operations EBITDA (₹ crores) PAT (₹ crores) (₹ crores) 13.6% 12.4% 13.3% 15.4% 8.4% 8.0% 7.3% 8.7% Margin +38% 1,081 926 +44% 167 801 123 +39% 94 99 68 411 64 56 35 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 FY21 FY22 FY23 FY24 ROE/ROCE (%)1 Fixed Asset
Slide 22: Growth Strategies
Dg ac all = Br a5 > a &) Growth Strategies “(e) CAPTAB
Slide 23: Multiple Levers for Growth
Multiple Levers for Growth 01. Expansion of Manufacturing Capabilities 02. Expansion of Wallet Share 03. Continued Focus on R&D o To expand business with existing o To expand research activities for both o CDMO is an essential segment of the customers while also cultivating new CDMO and Internationa
Slide 24: Growth Fueled by Capacity Expansion
Growth Fueled by Capacity Expansion Baddi Plant Dehradun | Taloja Plant Greenfield project at Jammu 20% - 25% 15% - 20% 20%-30% ₹ 865 crores ₹ 190 crores* 70% - 75% 40%-50% 70%-75% 50% -60% 70% - 75% Capacity 45% - 50% Utilization 50% - 60% FY24 Un-utilized Capacity Optimum Utilization Commenced Ram
Slide 25: Historical Financial Performance
Historical Financial Performance 24
Slide 26: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crores) FY24 FY23 FY22 FY21 Revenue from Operations 1,081.3 926.4 800.5 410.7 Other Income 12.5 9.2 2.9 1.4 Total Revenue 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 728.3 691.6 617.9 310.7 Employee Cost 90.7 54.8 40.5 22.3 Other Expen
Slide 27: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ crores) FY24 FY23 FY22 FY21 Equity & Liabilities (₹ crores) FY24 FY23 FY22 FY21 Non - Current Assets 741.1 261.9 196.4 99.1 Total Equity 830.9 276.5 208.6 144.8 Property, plant and equipment 291.6 150.1 156.6 76.4 Share Capital 57.2 48.0 12.0 12.0 Right of use as
Slide 28: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (₹ crores) FY24 FY23 FY22 FY21 Net Profit Before Tax 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items -37.2 -25.9 -15.3 -9.6 Operating profit before working capital changes 166.7 117.7 101.0 55.9 Changes in worki
Slide 29: Industry Overview
Dg ac all = Br a5 > a &) Industry Overview “(e) CAPTAB
Slide 30: Indian Formulations Market – Poised for Healthy Growth
Indian Formulations Market – Poised for Healthy Growth Domestic Formulations Market to Grow at Double Digit Rate (₹ Tn) Indian Formulations Exports Trend (USD Bn) 25.0 -27.0 19.1 13.0-15.0 12.9 10.6 1.04 1.47 2.6 – 2.7 6.9 11.0-13.0 8.5 CAGR: 7.5% CAGR: 10-12% 6.0 FY2016 FY2021 FY2026E Semi-regulate
Slide 31: Indian CDMO Market – Overview
Indian CDMO Market – Overview Outsourcing of production activities to third-party vendors Big pharmaceutical companies prefer to outsource R&D as well as manufacturing activities in order to move to an asset light model. Most contract development and manufacturing organizations (CDMOs) cater to the
Slide 32: Indian CDMO Market Expected to sustain its Strong Growth Trajectory
Indian CDMO Market Expected to sustain its Strong Growth Trajectory Review and outlook on Indian CDMO market (₹ Bn) Key Growth Drivers FY23 – FY28: ~12-14% CAGR Rising trend of outsourcing among the pharmaceutical industry players 2,400 – 2,500 Rising demand for generics FY18 – FY23: ~14% CAGR 1,310
Slide 33: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg Em